Polyethylene glycol-interferon: current status in hepatitis C virus therapy (Q35020845)

5 August 2017

1 reference

title

Polyethylene glycol-interferon: current status in hepatitis C virus therapy (English)

1 reference

5 August 2017

1 reference

4

Michael P Manns

1 reference

5 August 2017

1

Heiner Wedemeyer

1 reference

5 August 2017

3

Markus Cornberg

1 reference

5 August 2017

Johannes Wiegand

2

1 reference

5 August 2017

publication date

1 December 2002

1 reference

Journal of Gastroenterology and Hepatology

5 August 2017

published in

1 reference

5 August 2017

volume

17 Suppl 3

1 reference

5 August 2017

page(s)

S344-50

1 reference

10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.26.X

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.26.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.26.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.26.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.26.X

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.26.X

The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.26.X

Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.26.X

Clinical outcomes after transfusion-associated hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.26.X

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.26.X

Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.26.X

Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.26.X

Nonresponse to interferon in chronic hepatitis C: re-treatment redux

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.26.X

Treatment of chronic hepatitis C virus infection in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.26.X

Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.26.X

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.26.X

A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.26.X

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.26.X

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.26.X

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.26.X

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.26.X

Treatment of acute hepatitis C with interferon alfa-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.26.X

The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.26.X

Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.26.X

Identification of the major positional isomer of pegylated interferon alpha-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.26.X

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.26.X

10.1046/J.1440-1746.17.S3.26.X

21 January 2018

Identifiers

DOI

1 reference

release_2gqjvi7oszbz3jpq2yylfbb45q

5 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2gqjvi7oszbz3jpq2yylfbb45q

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference